This review discusses current strategies, new advancements and clinical trials for the treatment of bone metastases.
Method
We performed a narrative review using literatures obtained from PubMed and Google Scholar using the terms such as “Prostate cancer”, “bone metastases”, “treatment”. The search included articles between 2000 and 2024. For clinical trial information, we searched www.clincialtrial.gov and included trials of Prostate cancer and bone metastases.
Summary
We go through the mechanisms of action, clinical effectiveness, and limitations of current and emerging therapies, including bisphosphonates, Receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitors, novel agents and Prostate-Specific Membrane Antigen (PSMA) targeted approaches. By examining recent research and ongoing clinical trials, we seek to inform the development of optimized treatment strategies and guide future research directions. The review discuss about novel agents such as Radium-223 and Lutetium-177. Lutetium-177 is emerging as a promising treatment for metastatic prostate cancer with bone involvement. These treatment options offer significant survival benefits in patients with bone-dominant metastatic prostate cancer. The review also explores combination treatments, where integrating bone-targeted therapies with systemic prostate cancer treatments holding potential for enhanced efficacy. Ongoing clinical trials investigating novel treatment options and advanced drug delivery techniques are highlighted.
Conclusion
The advancements signify a promising direction in the treatment of bone metastases in prostate cancer, highlighting the need for continuous innovation to enhance patient care and outcomes
RawlaP. Epidemiology of prostate cancer. World J Oncol2019; 10: 63–89.
2.
BubendorfLSchöpferAWagnerU, et al.Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol2000; 31: 578–583.
3.
CroucherPIMcDonaldMMMartinTJ. Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer2016; 16: 373–386.
4.
HicksFBrueraEHigginsonI, et al.Textbook of palliative medicine. Palliat Med2008; 22: 99–100.
5.
DePuyVAnstromKJCastelLD, et al.Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer2007; 15: 869–876.
6.
MaoLWangLXuJ, et al.The role of integrin family in bone metabolism and tumor bone metastasis. Cell Death Discov2023; 9: 119.
7.
KayamoriKSakamotoKNakashimaT, et al.Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells. Am J Pathol2010; 176: 968–980.
8.
NissensonRA. Parathyroid hormone and parathyroid hormone-related protein. In: Osteoporosis. Stanford, CA: Stanfond University School of Medicine, 2001, pp.221–246.
9.
YangCTianYZhaoF, et al.Bone microenvironment and osteosarcoma metastasis. Int J Mol Sci2020; 21: 6985.
10.
BoyceBFXingL. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys2008; 473: 139–146.
11.
LinSCYu-LeeLYLinSH. Osteoblastic factors in prostate cancer bone metastasis. Curr Osteoporos Rep2018; 16: 642–647.
12.
RobertsECossignyDAQuanGM. The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton. Prostate Cancer2013; 2013: 418340.
13.
TrivediTPagnottiGMGuiseTA, et al.The role of TGF-β in bone metastases. Biomolecules2021; 11: 1643.
SaadFGleasonDMMurrayR, et al.Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst2004; 96: 879–882.
16.
RosenLSGordonDTchekmedyianNS, et al.Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized phase III double-blind, placebo-controlled trial. Cancer2004; 100: 2613–2621.
17.
YangLDuS. Efficacy and safety of zoledronic acid and pamidronate disodium in the treatment of malignant skeletal metastasis: a meta-analysis. Medicine (Baltimore)2015; 94: e1822.
18.
RussellRGWattsNBEbetinoFH, et al.Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int2008; 19: 733–759.
19.
MorganCWagstaffJ. Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?Acta Oncol (Madr)2009; 48: 882–889.
KhanAAMorrisonAHanleyDA, et al.Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res2015; 30: 3–23.
22.
MachereySMonsefIJahnF, et al.Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev2017; 1: 24.
StopeckATLiptonABodyJJ, et al.Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol2010; 28: 5132–5139.
25.
HegemannMBedkeJStenzlA, et al.Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. Ther Adv Urol2017; 9: 81–88.
26.
MercurioMFamiliariFde FilippisR, et al.Improvement in health status and quality of life in patients with osteoporosis treated with denosumab: results at a mean follow-up of six years. Eur Rev Med Pharmacol Sci2022; 26: 16–23.
27.
FuPAShenCYYangSR, et al.Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw. Sci Rep2023; 13: 8403.
28.
McCalebRVJohnsonJT. Severe, prolonged, denosumab-induced hypocalcemia with recovery after 111 days of high-dose calcium supplementation. AACE Clin Case Rep2019; 5: e82–e85.
WadhwaRGuptaNDixitJ, et al.Cost-Effectiveness analysis of denosumab in the prevention of skeletal-related events among patients with breast cancer with bone metastasis in India. JCO Glob Oncol2024; 10: e2300396.
31.
HyväkkäAKääriäinenOSUtriainenT, et al.Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: a real-world evidence multicenter study. Cancer Med2023; 12: 4064–4076.
Canadian Agency for Drugs and Technologies in Health. Radium-223 for patients with castration resistant prostate cancer with bone metastases: a review of clinical effectiveness, cost-effectiveness and guidelines. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health, 2016. APPENDIX 10, Guidelines and Recommendations for Radium-223 for Treatment of Patients with Bone Metastatic CRPC, https://www.ncbi.nlm.nih.gov/books/NBK401498/.
34.
NilssonSCisloPSartorO, et al.Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol2016; 27: 868–874.
35.
RahbarKAhmadzadehfarHKratochwilC, et al.German Multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med2017; 58: 85–90.
36.
SardinhaMDos ReisAFBarreiraJV, et al.Antibody-drug conjugates in prostate cancer: a systematic review. Cureus2023; 15: 5.
37.
SartorODe BonoJChiKN, et al.Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med2021; 385: 1091–1103.
38.
KindFMichalskiKYousefzadeh-NowshahrE, et al.Bone marrow impairment during early [177Lu] PSMA-617 radioligand therapy: haematotoxicity or tumour progression?EJNMMI Res2022; 12: 20.
39.
HerrmannKRahbarKEiberM, et al.Renal and multiorgan safety of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the VISION dosimetry substudy. J Nucl Med2024; 65: 71–78.
CaoJChenYHuM, et al.177Lu-PSMA-RLT Of metastatic castration-resistant prostate cancer: limitations and improvements. Ann Nucl Med2021; 35: 861–870.
42.
AdlerRA. Management of osteoporosis in men on androgen deprivation therapy. Maturitas2011; 68: 143–147.
43.
VijayaraghavaluSGaoYRahmanMT, et al.Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis. Biomaterials2020; 227: 119558.
44.
JamesNDPirrieSJPopeAM, et al.Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: the TRAPEZE randomized clinical trial. JAMA Oncol2016; 2: 493–499.
45.
SmithMParkerCSaadF, et al.Addition of radium-223 to Abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol2019; 20: 408–419.
46.
TombalBFLoriotYSaadF, et al.Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis.
47.
QianYBhowmikDKachruN, et al.Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States. Support Care Cancer2017; 25: 1845–1851.
GravestockPClarkEMortonM, et al.Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial. NIHR Open Res2023; 2: 49.
McCarthyI. The physiology of bone blood flow: a review. JBJS2006; 88: 4–9.
56.
GriffinMOCeballosGVillarrealFJ. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res2011; 63: 102–107.
57.
FarrellKBKarpeiskyAThammDH, et al.Bisphosphonate conjugation for bone specific drug targeting. Bone Rep2018; 9: 47–60.
58.
YamashitaSKatsumiHHibinoN, et al.Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis. Biomaterials2018; 154: 74–85.
59.
PetrylakDPKantoffPVogelzangNJ, et al.Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. Prostate2019; 79: 604–613.
